Calculating of Correlations Between ADR, PDR, MAP
Launched by HOSPITAL FRYDEK-MISTEK · Oct 26, 2018
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
ADR (adenoma detection rate) is generally accepted quality indicator. For possible gaming with ADR other indicators are needed. MAP (mean adenoma per colonoscopy) reflects the quality of examination of entire colon and is considered to be the most objective quality indicator. The aim of our study is to compare MAP with ADR and PDR (polyp detection rate) of all colonoscopists in our department.
We want to retrospectively assess the quality indicators of all colonoscopies from January 2013 to December 2017. We want to calculate ADR, PDR and MAP of all our endoscopists for all colonoscopies i...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • people over 50 years of age coming for colonoscopic examination (screening, surveillance, diagnostic)
- Exclusion Criteria:
- • age under 50 years
- • indication for colonoscopy: therapeutic, IBD, management of complications and sigmoidoscopies
About Hospital Frydek Mistek
Hospital Frydek-Mistek is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. Located in the heart of the Czech Republic, the hospital is committed to enhancing patient outcomes by exploring new therapies and treatment protocols across various medical disciplines. With a focus on patient safety and ethical standards, Hospital Frydek-Mistek collaborates with a multidisciplinary team of experienced healthcare professionals, researchers, and regulatory bodies to ensure the highest quality of care and scientific rigor in its clinical investigations. By participating in groundbreaking studies, the hospital aims to contribute to the global medical community and improve health outcomes for patients both locally and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Frýdek Místek, , Czechia
Patients applied
Trial Officials
Ivana Mikoviny Kajzrlikova
Principal Investigator
Doctor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials